Improved arteriogenesis with simultaneous skeletal muscle repair in ischemic tissue by SCL plus multipotent adult progenitor cell clones from peripheral blood by Huss, Ralf et al.
Research Paper
J Vasc Res 2004;41:422–431
DOI: 10.1159/000081441
Improved Arteriogenesis with Simultaneous
Skeletal Muscle Repair in Ischemic Tissue by
SCL+ Multipotent Adult Progenitor Cell Clones
from Peripheral Blood
Ralf Hussa Matthias Heilb Sabine Moosmanna Tibor Ziegelhoefferb
Sabine Sagebiela Christian Seligera Sarah Kinstonc Berthold Gottgensc
aInstitute of Pathology, University of Munich, Munich, bMax Planck Institute for Physiology and Experimental
Medicine, Department of Experimental Cardiology, Bad Nauheim, Germany; cCambridge Institute for Medical
Research, Department of Haematology, Cambridge University, Cambridge, UK
Received: June 2, 2004
Accepted after revision: August 13, 2004
Published online: October 11, 2004
Dr. Ralf Huss
Institute of Pathology, University of Munich, Thalkirchner Strasse 36
DE–80337 Munich (Germany)
Tel. +49 89 5160 4053, Fax +49 89 5160 4043
E-Mail Ralf.Huss@patho.med.uni-muenchen.de
ABC
Fax + 41 61 306 12 34
E-Mail karger@karger.ch
www.karger.com
© 2004 S. Karger AG, Basel
1018–1172/04/0415–0422$21.00/0
Accessible online at:
www.karger.com/jvr
Key Words
Adult stem cells W MAP-C W Arteriogenesis W SCL W Tissue
repair
Abstract
Background: The CD34– murine stem cell line RM26
cloned from peripheral blood mononuclear cells has been
shown to generate hematopoietic progeny in lethally irra-
diated animals. The peripheral blood-derived cell clones
expresses a variety of mesodermal and erythroid/myeloid
transcription factors suggesting a multipotent differentia-
tion potential like the bone marrow-derived ‘multipotent
adult progenitor cells’ (MAP-C). Methods: SCL+ CD34–
RM26 cells were transfused intravenously into mice suf-
fering from chronic hind-limb ischemia, evaluating the
effect of stem cells on collateral artery growth and simul-
taneous skeletal muscle repair. Results: RM26 cells are
capable of differentiating in vitro into endothelial cells
when cultured on the appropriate collagen matrix. Activa-
tion of the SCL stem cell enhancer (SCL+) is mediated
through the binding to two Ets and one GATA site and cells
start to express milieu- and growth condition-dependent
levels of the endothelial markers CD31 (PECAM) and Flt-1
(VEGF-R1). Intravenously infused RM26 cells significantly
improved the collateral blood flow (arteriogenesis) and
neo-angiogenesis formation in a murine hind-limb isch-
emia transplant model. Although transplanted RM26 cells
did not integrate into the growing collateral arteries, cells
were found adjacent to local arteriogenesis, but instead
integrated into the ischemic skeletal muscle exclusively
in the affected limb for simultaneous tissue repair. Con-
clusion: These data suggest that molecularly primed
hem-/mesangioblast-type adult progenitor cells can circu-
late in the peripheral blood improving perfusion of tissues
with chronic ischemia and extending beyond the vascular
compartment.
Copyright © 2004 S. Karger AG, Basel
Introduction
‘Stem cell plasticity’ is a controversial issue in applied
biology with major implications for clinical medicine in
the future. Hematopoietic stem cells (HSC) are routinely
isolated from the bone marrow, peripheral blood and
umbilical cord blood, either unselected or based on the
expression of stem cell associated antigens, e.g. CD34.
There is evidence that it is also possible to achieve hema-
topoietic reconstitution with large numbers of CD34–
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stem cells, which are considered to be ‘adult stem cells’,
based on their mesenchymal co-phenotype [1]. Recent
reports have suggested that adult stem cells have a consid-
erable degree of pluripotency and plasticity, which appar-
ently allows the generation of a variety of tissue- and
organ-specific progenitors in vivo and adult stem cells are
supposed to maintain a steady state of organ function
after injury or disease [2, 3].
CD34–, stroma-like cells from the canine bone marrow
can give rise to CD34+ hematopoietic precursor cells [4–
6]. Despite in vitro evidence, the gold standard to prove
any biological function is in vivo reconstitution of organs,
e.g. the lympho-hematopoietic system with HSCs. We
cloned the CD34– murine cell line RM26 and achieved
hematopoietic recovery of syngeneic mice [7]. This pro-
genitor cell clone does not express any lineage specific
markers in vitro (lin–), but the Sca-1 antigen (Sca-1+),
identifying stem cells in certain mouse strains. Immortali-
zation with the SV40 large-T antigen did not interfere
with the potential pluripotency and multilineage differen-
tiation capability. Similarly, a cloned canine cell line from
peripheral blood was also used for an autologous trans-
plantation resulting in cells coexpressing mesenchymal
markers in vitro and in vivo, e.g. osteocalcin [8]. To
extend these studies to the human system, we generated a
cloned equivalent from human peripheral blood cells [9].
When maintained in culture, this clonal cell line is com-
posed of a small Rho123 low, CD34+ subpopulation and a
Rho123high, CD34– major population. Interestingly, the
transcription factors GATA-1, -2, -3 were only expressed
in the Rholow population, suggesting a commitment to-
wards the hematopoietic lineage. By contrast, the Rhohigh
major population expressed Tie-1 and VEGF mRNA.
While VEGF seems to regulate HSC survival by an inter-
nal autocrine loop, the expression of the VEGF-R2
(KDR) was shown on primitive stem cells [10]. Tie-1 is
also present on endothelial cells and hematopoietic pro-
genitors [11], which draws attention to the hemangioblast
as a potential pluripotent stem cell with a distinct plastici-
ty between the hematopoietic and mesenchymal lineage.
The hemangioblast, a common progenitor of blood and
endothelial cells, has been identified in frog embryos as
well as in mouse embryonic stem cells [12] and recently in
human fetus and adult bone marrow cells [13, 14]. More-
over, the close relationship of blood and endothelial cells
is underlined by the discovery of hemogenic endothelium
in mouse, chick and human embryos, where differen-
tiated endothelial cells give rise to the HSCs of the defini-
tive hemopoietic system [15]. Several genes have been
shown to be critical regulators of both hemopoiesis and
vasculogenesis (e.g. Flk-1, Tie-1, SCL, LMO-2), including
the bHLH transcription factor SCL [16]. The close corre-
lation between endothelial and HSC/progenitor cells is
further underlined by the observation that a 640-bp
enhancer has been identified 3) of the mouse SCL gene,
which directs expression to hemangioblasts in transgenic
animals. The activity of this enhancer critically depends
on three regions, which are postulated to enable the for-
mation of a multiprotein complex containing Ets and
GATA transcription factors [17].
Here we have investigated the possible relationship
between the clonal RM26 cell line obtained from circulat-
ing adult cells and functional adult hemangioblast-like
stem cells, which also circulate in the peripheral blood
and are recruited to a site of lesion (tissue regeneration).
Methods
Matrigel Assay
Matrigel™ was purchased from Becton-Dickinson (# 354635)
and used to coat 24-well plates following the manufacturer’s instruc-
tions. RM26 cells were trypsinized and 20,000 or 40,000 cells were
added per well of the coated 24-well plate. Cells were photographed
after 16 h to monitor angiogenic activity using a Nikon inverted
microscope linked to a Fuji digital camera.
RT-PCR Survey
For first strand synthesis 1–2 Ìg RNA from RM26 cells was dis-
solved in 9.7 Ìl volume together with 2 Ìl random hexamers (100 ÌM
stock, Amersham Pharmacia Biotech) and incubated at 65°C for
20 min before the samples were centrifuged for 10 s and placed on
ice. In the second step 5! first-strand buffer (Gibco kit cat. No
28025-013) was mixed with 2 Ìl 0.1 M DTT (1,4-dithio-DL-treitol;
Sigma, Deisenhofen, Germany), 1 Ìl M-MLV RT, 0.8 Ìl 25 mM
dNTPs (Amersham) and 0.5 Ìl RNasin (Promega). This mixture was
added to the solution from step 1 and incubated together at 37°C for
90 min, then at 70°C for 10 min and finally stored at –20°C. The
PCR reaction was performed in 0.2-milliliter thin-wall tubes with
2.5 Ìl of 10! buffer II, 1.5 Ìl MgCl2, 0.5 Ìl dNTPs (10 ÌM stock),
0.2 Ìl Amplitaq gold and 1 Ìl first-strand cDNA or water (negative
control) or RNA (no RT-control) in 18.3 Ìl water. One microliter of
each forward and reverse primer from the designed transcription
product was added from a 25-ÌM stock solution. The PCR program
ran for 30 cycles with an annealing temperature of 56°C for 30 s and
an amplification temperature of 70°C, also for 30 s. The samples
were then run on a 2% agarose gel. Primer sequences were available
with the authors.
Reporter Assay and EMSA Analysis
Stable transfections and luciferase assays were performed as
described. A total of eight independent pools of stably transfected
cells were assayed for each construct. The complexity of pools was
assessed by limiting dilution and found to be in excess of 50 for each
electrophoration. Standard nuclear extracts were prepared and
EMSA (electrophoretic mobility shift assay) was performed.
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Fig. 1. Endothelial differentiation of RM26
cells in vitro. a RM26 cells under standard
growth conditions in the cell culture without
any differentiation-inductive matrix (origi-
nal magnification, !100). b RM26 cells
grown on an angiogenic-inductive matrix
(Matrigel assay) forming extensive networks
indicative of endothelial cells (original mag-
nification, !50).
Flow Cytometry of RM26 Cells
RM26 cells were cultured without serum or in the presence of
10% fetal calf serum (FCS) (purchased from PAN-Biotech GmbH,
Germany) for 24 h until 80% cell density or complete confluency.
RM26 cells were trypsinized, thoroughly washed at least three times
in phosphate-buffered saline (PBS) and stained with directly labeled
antibodies against CD31 (PE labeled), CD34 (FITC labeled) and
VEGF-R1 (PE labeled) (purchased from Becton-Dickinson, Heidel-
berg, Germany) for 30 min in FACS buffer (PBS, 2% FCS, 0.05%
Na-Azid). Cells were washed afterwards in FACS buffer and finally
resuspended in 300 Ìl FACS buffer. 100,000 cells of each sample
were used for analysis by flow cytometry (FACScan, Becton Dickin-
son, Cellquest Software).
Transplantation of RM26 Cells into Host Animals
The capability of RM26 cells to stimulate collateral artery growth
was tested in a mouse peripheral artery disease model as previously
described [18]. In brief, the right femoral artery of anaesthetized
Balb/c mice was exposed and ligated distal to the arteria profunda
femoris. RM26 cells (0.5 ! 106/mouse) were labeled with the PKH2
green fluorescent cell linker kit (Sigma, Deisenhofen, FRG) accord-
ing to the manufacturer’s instructions and were injected into a tail
vein directly after operation. To characterize the perfusion recovery
in this chronic ischemia model, relative blood flow was measured in
the footpad before, directly after ligation, and on postoperative days
7, 14 and 21 using a laser Doppler imager [18]. Finally, for tissue
harvesting mice were heparinized and euthanized. After the prepara-
tion and cannulation of the aorta, tissue was perfused for 5 min with
PBS containing 0.1% adenosine to achieve maximal vasodilatation,
followed by 20 min perfusion with pFA (2% in PBS) and the adduc-
tor and gastrocnemius muscles were sampled.
Immune Histochemistry
Collateral artery formation during arteriogenesis was visualized
by the immunostaining of smooth muscle cells in the vessel wall with
an antibody against ·-smooth muscle actin (HHF). The mouse tissue
from the adductor region containing the growing collateral arteries
was excised from the animals and initially frozen in TissueTec® and
later fixed in 4% paraformaldehyde prior to paraffin embedding.
0.5-Ìm-thick sections were sliced from the paraffin block and slides
were deparaffinized in xylene and dried in ethanol. Endogenous per-
oxidase activity was blocked by 3% H2O2. Antigen retrieval was per-
formed by placing the slides in a coplin jar containing citrate buffer
and heating the jar in a microwave oven (700 W) to 95°C for 15 min.
Smooth muscle actin was stained with an anti-·-HHF antibody
(Roche, Germany; # 1148818). Specific staining was detected with a
secondary IgG/Biotin F(ab)2 (Dako, Hamburg, Germany; E0413)
and visualized in AEC-solution (Dako).
To visualize the transplanted cells in different tissues after for-
malin fixation and paraffin embedding, we used an indirect immu-
noperoxidase method (Picture PLUS Kit, Zymed, San Francisco,
Calif., USA). Endogenous peroxidase activity was also blocked by
3% H2O2. Transplanted cells were finally detected by an unconju-
gated primary monoclonal mouse anti-SV40 antibody (Oncogene
Research Products, Boston, Mass., USA). Optimum labeling of SV40
staining was obtained after microwave pretreatment [two cycles of 15
min in Target Retrieval Solution (Dako)]. SV40 peroxidase activity
was detected by the addition of the Vector VIP substrate kit (Vector
Laboratories, Burlingame, Calif., USA).
Immunohistochemical staining for myoglobin (staining skeletal
and cardiac muscle) was achieved with a polyclonal myoglobin anti-
body (Dako). Sections were incubated for 1 h at room temperature
diluted in DakoCytomation Antibody Diluent with Backround Re-
ducing Components (Dako). Myogenin was detected by Liquid AEC
Chromogene Kit (BioGenex, San Ramon, Calif., USA). The sections
were then counterstained with hematoxylin.
Results
Matrix-Induced Differentiation with Endothelial
Phenotype
RM26 cells were derived from peripheral blood mono-
nuclear cells. When cultured, RM26 cells display a fibro-
blast-like morphology, while transplanted RM26 cells
were able to generate hematopoiesis in the appropriate in
vivo model. Here, we assessed the endothelial differentia-
tion potential of RM26 cells using the matrigel assay.
RM26 cells readily formed extensive networks (fig. 1), a
phenotype typically associated with endothelial cells. En-
dothelial networks were established after only 12 h, sug-
gesting that at least a substantial proportion of RM26 cells
have an angioblast/hemangioblast phenotype when main-
tained in culture.
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Gene Expression Profile of the Murine Adult Stem Cell
Clone RM26
Next, we performed an extensive gene expression survey
of RM26 cells to assess whether the apparent bi-potential
differentiation capacity to both hematopoietic and endo-
thelial lineages was reflected in the gene expression pattern
for those two differentiation processes. This comprehen-
sive analysis demonstrated that RM26 cells expressed
markers for both hematopoietic and endothelial cells (ta-
ble 1) as well as some primitive mesodermal markers and a
large number of genes known to be coexpressed on endo-
thelial and hematopoietic progenitor cells. This observa-
tion is consistent with a model suggesting that, when grown
in culture, subpopulations of RM26 cells differentiate
down the hematopoietic and endothelial lineages.
The SCL Stem Cell Core Enhancer Is Active in RM26
Cells
We investigated whether the SCL stem cell core en-
hancer was also active in RM26 cells. As shown in fig-
ure 2, the 640-bp stem cell enhancer fragment was active
in stable transfection assays giving approximately 4-fold
higher activity than the minimal promoter control (com-
pare SV/luc/SH0.6 with SV/luc). Moreover, analysis of
mutant enhancer fragments demonstrated that mutations
in the regions 1–3 each individually reduced the enhancer
activity between 2- and 4-fold. Regions 1 and 2 contain
Ets factor consensus-binding sites, while region 3 contains
a GATA factor-binding site. Each individual motif is crit-
ical for enhancer activity in hemangioblasts. The data pre-
sented here suggest that the activity of the SCL stem cell
enhancer in RM26 critically depended on Ets and GATA
factors binding to regions 1, 2 and 3. Given the fact that
there is also a Myb consensus-binding site in region 1, we
wanted to confirm the role of Ets factors in regulating
stem cell enhancer activity in RM26. We performed elec-
trophoretic mobility shift assays using RM26 nuclear
extracts and radiolabeled oligonucleotides corresponding
to regions 1 and 2. One specific complex was identified
binding to region 1. Competition experiments using oligo-
nucleotides with specific mutations in only the Myb site
(1m oligomer) or only the Ets site (1e oligomer) demon-
strated that this complex bound to the GGAT ets consen-
sus site. Band shift analysis with the region 2 oligo identi-
fied three major complexes (fig. 3, compare lanes 1–3).
However, only one of these was not competed by the
mutant oligo carrying the exact mutation that gave rise to
the reduced enhancer activity in transfection assays. This
complex was, therefore, likely to correspond to an Ets fac-
tor binding to the GGAA Ets consensus site.
Table 1. RT-PCR survey of RM-26 gene expression
RM26 E11.5
Mesodermal markers HPRT Y Y
BMP RIA Y Y
BMP-4 Y Y
Smad1 Y Y
Erythroid/myeloid genes ˙ globin Y Y
· globin Y Y
ß H1 globin N Y
ÂÁ2 globin N Y
ß major globin N Y
MPO N Y
Lysozyme Y Y
vav N Y
Epo R Y Y
Transcription factors Scl Y Y
GATA-1 N Y
GATA-2 Y Y
GATA-3 Y Y
GATA-4 N N
GATA-5 Y Y
GATA-6 Y Y
PU.1 N Y
EKLF Y Y
c-myb Y Y
LMO2 Y Y
Ets1 Y Y
Ets2 Y Y
Fli1 Y Y
Erg N Y
Elf-1 Y Y
Tel Y Y
Elk1 N Y
ERM N Y
Elf-2 N Y
Elf-3 N Y
Endothelial markers VEGF-R Y Y
Flk-2/Flt3 N N
CD31 Y Y
Tie-1 N Y
Tie-2 Y Y
Flt-1 N N
Thrombomodulin Y Y
VE-cadherin Y Y
vWF Y Y
VEGF Y Y
HSC markers CD34 Y Y
c-kit Y Y
Total RNA was prepared from RM26 and whole fetal mouse cells
(E11.5) and analyzed by RT-PCR. Monoclonal RM26 cells seem to
be more immature and less committed to hematopoiesis/myelopoie-
sis than the entire E11.5 population. The degree of general transcrip-
tional activity is also lower in the predominantly quiescent CD34–
population, but with the potential of endothelial precursor cells.
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Fig. 2. Active SCL stem cell core enhancer
in RM26 cells. The top part of the figure
illustrates the location of the +19 core en-
hancer 3) of the mouse SCL locus together
with a human/mouse alignment indicating
the three conserved sequence blocks with
Ets, Ets and GATA family transcription fac-
tor-binding sites (regions 1–3). The lower
part summarizes the results from luciferase
reporter gene studies showing that the +19
core enhancer (SV/luc/SH0.6) is approxi-
mately 4-fold more active than the minimal
promotor control plasmid (SV/luc). More-
over, mutations in regions 1–3 all signifi-
cantly inhibited enhancer activity (see SV/
luc/SH0.6mut; 1–3).
Surface Expression of Endothelial Markers
RM26 cells were analyzed for the expression of differ-
ent endothelial surface markers such as CD31 (PECAM),
CD34 and VEGF-R1 without or in the presence of 10%
FCS for 1, 24 and 48 h. In the presence of serum, RM26
cells showed a strong spontaneous expression of different
endothelial markers after 24 h (fig. 4), while only few
RM26 cells expressed CD31, CD34 or VEGF-R1 in the
absence of FCS. RM26 cells seize to grow in cell culture
after serum starvation or when grown at low plating
density.
Fig. 3. Ets-family transcription factors bind to regions 1 and 2 in
RM26 cells. Electrophoretic mobility shift assays using a radiola-
beled oligo for region 1. a Single complex (I) was identified, binding
of which was competed by excess w.t. (wild-type) or myb-mutant
oligos (1m), but not by excess Ets mutant oligomers (1e). b Electro-
phoretic mobility shift assays using a radiolabeled oligo for region 2.
Three complexes were bound and competed by excess w.t. oligos.
Only complex II, however, was specific for the mutation used in the
functional studies as it was not competed by excess mutant oligo-
mers (2).
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Fig. 4. Expression of endothelial-associated
proteins on RM26 cells. RM26 cells express
moderate levels of CD34 and CD31 (a) and
VEGF-R1 (b) grown in culture for 24 h at
intermediate cell density without serum. In
the presence of serum, CD31 expression (c)
and VEGF-R1 expression (d) increase signif-
icantly, suggesting a more angiogenic envi-
ronment.
Effects of RM26 Cells on Collateral Blood Flow
RM26 cells were injected via the tail vein into mice
directly after ligation of the right femoral artery. Blood
perfusion of the mouse hind-limb after femoral artery
ligation was then assessed before, immediately after oper-
ation and on postoperative days 7, 14, and 21 by laser
Doppler imaging in mice injected with RM26 cells and in
control animals. Blood flow ratio (right vs. left; R/L)
decreased in both groups (n = 6) immediately after liga-
tion of the femoral artery [0.17 B 0.02 (control) vs. 0.15
B 0.02 (RM26)]. On day 7, blood flow in the RM26-
treated group was significantly improved when compared
to controls (0.52 B 0.07 vs. 0.66 B 0.07). This difference
continued to increase during the observation period
(fig. 5a). However, accelerated formation of large collater-
al vessels (improved arteriogenesis) was observed histo-
morphologically, particularly in the adductor muscles,
only in the operated limb, which had been exposed to high
shear forces due to the redirected blood flow after occlu-
sion of the femoral artery (fig. 5b). Semi-quantitative
analysis of arterial vessel size and vessel density revealed
an approximate 20% improvement of both parameters in
mice that received a stem cell transplantation. Fluores-
cent or SV40(+) RM26 cells could not be detected as an
integrated part of these differentiated collaterals, but clus-
ters of SV40(+) cells were found adjacent to arteriogenesis
(fig. 5c, d). The infusion of stem cells 1 day later after
arterial ligation had no effect on arteriogenesis.
Integration of RM26 Cells in Skeletal Muscle
Prior to infusion, RM26 cells were labeled with the
green fluorescent dye PKH2. The gastrocnemii muscles of
both limbs were harvested after termination of the experi-
ment and sections of the muscles were analyzed by con-
ventional and fluorescence microscopy also after addi-
tional immunohistochemistry. As figure 6a shows, iso-
lated green fluorescent cells were found integrated into
the skeletal muscle at the affected limb, while trans-
planted stem cells could also not be detected in other mus-
cular tissue, i.e. in the contralateral limb or other paren-
chymal organs. Conventional serial sections revealed a
regular striated muscular differentiation only with signs
of atrophy, but with enlarged vessels in the vicinity
(fig. 6b). Regular striated muscle differentiation in the
areas with transplanted green cells was demonstrated by
regular myoglobin staining (fig. 6c) and SV40(+) nuclei
could be detected and localized in the gastrocnemius mus-
cle of the affected limb (fig. 6d).
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Discussion
The degree of plasticity of adult stem cells is still a mat-
ter of much controversy. However, there is evidence of
the differentiation potential of CD34– stem cells like
RM26 cells into various mesenchymal tissues [3], includ-
ing differentiation into endothelial cells during neo-angio-
genesis [20, 21]. Since the expression of the bHLH tran-
scription factor SCL amplifies the numbers of hemangio-
blasts during embryonic development [22], and we ob-
served that this key regulator of endothelial and heman-
gioblast function was indeed expressed in RM26 cells, this
cell population may represent functional hemangioblasts.
Although mesenchymal stem cells are routinely iso-
lated from bone marrow [23], RM26 cells were generated
from the peripheral blood [7, 24].
Fig. 5. Transplanted RM26 cells improve relative blood flow in
affected limb. a Blood flow ratio (R/L) in hind-limbs from mice with-
out treatment (blue bars) or after transplantation with RM26 cells
(red bars) as assessed by laser Doppler imaging postoperatively and
7, 14 and 21 days after femoral artery ligation. Mice that received
stem cell transplantation showed an improved relative blood flow in
the affected limb as a measure of accelerated collateral vessel forma-
tion. b Serial sections of the adductor muscle region in the ligated
limb show enlarged and growing vasculature with mild inflammation
and adjacent cells in the connective tissue (HHF staining; original
magnification, !25). Semi-quantitative analysis of vessel size and
density revealed an approximately 20% improvement of both pa-
rameters in mice that received a stem cell transplantation compared
to mice with chronic ischemia without additional stem cell treat-
ment. c Detection of SV40(+) nuclei (red) in cells adjacent to the
growing vasculature without evidence of RM26 cells incorporated
into the vessel walls (original magnification, !200). d Magnification
of c, showing unstained endothelial cells (dark violet nuclei) in two
small capillary vessels (open arrows) without integration of the
SV40(+) cells or pericytes (closed arrows) (original magnification,
!400).
Fig. 6. Integration of transplanted cells in striated skeletal muscle.
a Serial sections through the skeletal muscle of the m. gastrocnemius
in the affected limb show fluorescence-labeled striated muscle cells,
suggesting an integration of transplanted and PKH-2-stained RM26
cells into the ischemic and regenerating muscle already 3 days after
transplantation (original magnification, !200). b Conventional seri-
al sections of a revealed a regular striated muscular differentiation
with signs of mild atrophy, but with enlarged vessels in the close
proximity (HE; original magnification, !200). c Myoglobin staining
of serial sections from areas with PKH-2(+) muscle cells (original
magnification, !100). d Detection of SV40(+) nuclei from trans-
planted RM26 cells in regenerating skeletal muscle (original magnifi-
cation, !400). Open arrows show stained nuclei of the adjacent
striated muscle.
The Angiogenic Potential of CD34– Stem Cells
Similar to the results obtained in the human stem cells
[9], RM26 cells also express a variety of mesodermal and
erythroid/myeloid transcription factors, including SCL,
GATA-2, -3, -5 and -6, but also the endothelial markers
flt-1, PECAM-1 and Tie-1 (table 1). The expression of
these surrogate endothelial markers, e.g. PECAM-1 and
Flt-1 (VEGF-R1), is particularly high when the growth
conditions are favorable in vitro. Given the ease of endo-
thelial differentiation and tube activity in the matrigel
assay, the expression of endothelial marker genes and
most importantly the strong upregulation of those genes
in actively growing cultures, RM26 cells may indeed be
thought of as endothelial precursor cells. However, the
functional angiogenic properties of this murine stem cell
clone had to be proven ultimately in the appropriate in
vivo model of chronic hypoxia, as used in this study
(fig. 5a). Yolk sac-derived cell lines express SCL just as
RM26 cells. SCL is the key regulator of hemangioblast
formation [22] and the expression of SCL in hemangio-
blasts is mediated by a 3) enhancer, also termed the SCL
stem cell enhancer [17, 25], which was also found to be
active in RM26 cells. The studies presented here suggest
that activity of the SCL stem cell enhancer may be used as
a surrogate marker for the evaluation of hemangioblast
cell line models, while the hemangioblast (and RM26
cells) may be a common progenitor of hematopoietic and
endothelial cells [26].
Milieu-Dependent Differentiation in vivo
Collateral artery growth (arteriogenesis) has been
shown to be a potent adaptive blood vessel growth in
adult organisms to achieve sufficient blood flow recovery
after the occlusion of a major artery [27]. It has been
shown that recruitment of circulating blood cells, namely
monocytes, contributes to the enlargement of pre-existent
collateral anastomoses to true arteries by the augmenta-
tion of cells integrated in the vessel wall [18]. In contrast,
we were not able to identify RM 26 cells integrated into
the growing collateral artery. Instead a number of cells
adjacent to the improved arteriogenesis showed SV40(+)
nuclei as a sign of their RM26 origin. From this result we
concluded that collateral artery growth in this model may
not necessarily require the integration of circulating cells
but may rather be accomplished through proliferation of
the cells present in the pre-existent collateral arteriole.
The role of the RM26 cells may be supportive e.g. by
releasing stimulating and activating cytokines and growth
factors, which in turn then participate in creating an
inflammatory environment which is necessary for the
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enhancement of arteriogenesis. It was suggested that stem
cells reside as nonproliferating perivascular pericytes or
supporting cells adjacent to the growing vasculature, re-
leasing growth factors and stimulating the differentiation
and possibly proliferation of pre-existing angiogenic pro-
genitors [28, 29]. Such a growth factor candidate could be
the placental growth factor (PlGF), which is able to recruit
pre-existing and primed stem cells from other reservoirs
like the bone marrow [30], and is able to directly stimulate
arteriogenesis [31, 32]. Similar results were reported in a
recent study where implantation of bulk peripheral blood
mononuclear cells into ischemic hibernating myocardium
resulted in a significant reduction of the ischemic area
and the formation of new collateral blood vessels without
incorporation of the implanted cells into the newly
formed capillaries [33]. It was also reported recently that
bone marrow-derived stem cells provide functional hem-
angioblast activity in vivo [21] or tune the appropriate
arteriogenesis at the site of lesion [22]. Consistent with
this is the observation that impaired recruitment of bone
marrow-derived stem cells interferes with successful an-
giogenesis [33]. This is in contrast to the study by Iba et al.
[34], who injected peripheral blood-derived monocytes
along with platelets directly into the ischemic limb. Also
Ziegelhoeffer et al. [28] reported recently that bone mar-
row-derived cells do not incorporate into adult growing
vasculature, unless they become part of tumor neoangio-
genesis [28].
The Hemangioblast as a Stem Cell for Tissue
Regeneration and Organ Maintenance?
The SCL stem cell enhancer is active in the murine
stem cell line RM26, requiring the same Ets and GATA
sites implicated in the amplification of hemangioblasts
and initiation of angiogenic differentiation [17]. Although
the majority of stem cells in the bone marrow are quies-
cent and refractory to external signals [35], Jiang et al.
[36] propose that multipotent adult progenitors cells or
MAPCs from the bone marrow are the most potent mes-
enchymal stem cells. Soluble factors, like PlGF and other
angio-inductive factors, are also secreted by otherwise
quiescent bone marrow stromal cells and tissue fibro-
blasts, depending on secondary signals and the local
milieu.
Although we also did not show any integration of trans-
planted RM26 stem cells in our model despite growing
vasculature at the site of lesion and ischemia, Harraz et al.
[37] have shown that a subset of adult peripheral blood
leukocytes can integrate into the endothelium of blood
vessels. However, this incorporation requires the coinjec-
tion with CD34+ stem cells, indicating that leukocyte-leu-
kocyte (CD34–/CD34+) interactions are necessary for the
successful execution of the angiogenic program in vivo.
The principle of neovascularization via progenitor or
stem cells has been reported before. In the present study,
we found that RM26 cells are capable of inducing angio-
genesis in vitro and improve hind-limb perfusion in vivo.
Moreover, evidence of an intramuscular integration
might indicate a pleiotropic effect of RM26 in ischemic
muscles, extending beyond the vascular compartment.
Further studies are required to characterize the functional
relevance of the myocyte substitution capacity of RM26
cells.
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